Department of Geriatrics, Respiratory Medicine, Xiangya Hospital of Central South University, Changsha, China.
Department of Geriatrics, Xiangya Hospital of Central South University, Changsha, China.
Sci Rep. 2017 May 17;7(1):2027. doi: 10.1038/s41598-017-02290-2.
Several prognostic indicators have shown inconsistencies in patients of different genders with lung adenocarcinoma, indicating that these variations may be due to the different genetic background of males and females with lung adenocarcinoma. In this study, we first used the Gene-Cloud of Biotechnology Information (GCBI) bioinformatics platform to identify differentially expressed genes (DEGs) that eliminated gender differences between lung adenocarcinoma and normal lung tissues. Then, we screened out that transcription factor 21 (TCF21) is a hub gene among these DEGs by creating a gene co-expression network on the GCBI platform. Furthermore, we used the comprehensive survival analysis platforms Kaplan-Meier plotter and PrognoScan to assess the prognostic value of TCF21 expression in lung adenocarcinoma patients. Finally, we concluded that decreased mRNA expression of TCF21 is a predictor for poor prognosis in patients with lung adenocarcinoma.
一些预后指标在不同性别肺腺癌患者中表现出不一致性，表明这些差异可能是由于肺腺癌男性和女性的遗传背景不同所致。在这项研究中，我们首先使用生物技术信息基因云（GCBI）生物信息学平台来识别消除肺腺癌和正常肺组织之间性别差异的差异表达基因（DEGs）。然后，我们通过在 GCBI 平台上创建基因共表达网络，筛选出转录因子 21（TCF21）是这些 DEGs 中的一个枢纽基因。此外，我们使用综合生存分析平台 Kaplan-Meier plotter 和 PrognoScan 来评估 TCF21 表达在肺腺癌患者中的预后价值。最后，我们得出结论，TCF21 mRNA 表达降低是肺腺癌患者预后不良的预测指标。
